Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
69
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 46.30 | -0.50% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,486.49 | 254.60 | 0.49% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 23,997.75 | 318.17 | -1.31% |
| NASDAQ | 25,466.19 | 400.32 | 1.60% |
| Nikkei 225 | 61,714.16 | 465.57 | 0.76% |
| NZX 50 Index | 14,259.06 | 79.20 | 0.56% |
| S&P 500 | 7,619.38 | 98.45 | 1.31% |
| S&P/ASX 200 | 9,112.70 | 40.50 | -0.44% |
| SSE Composite Index | 3,689.17 | 8.52 | 0.23% |